Genome-wide Association Studies To Identify Major Genetic Determinants Of 5 Blinding Eye Diseases Using Pooled DNA
Funder
National Health and Medical Research Council
Funding Amount
$562,193.00
Summary
This project aims to find important genes for 5 diseases that can lead to blindness. We will use a cost-effective approach where samples from a large number of individuals with a given disorder are pooled (mixed together) and then compared on gene chips covering the whole genome to a pool of people who do not have the disease. Differences identified between the groups will point to genes causing that disease. We will identify any major genes for the 5 diseases being studied.
Non-invasive Therapy For Keratoconus – Ultrasound Enhanced Delivery Of Riboflavin To Cornea For Transepithelial Corneal Collagen Crosslinking
Funder
National Health and Medical Research Council
Funding Amount
$600,658.00
Summary
Keratoconus is a degenerative eye disease which causes corneal thinning. The disease causes visual distortions & loss of vision, and is commonly treated with Corneal Cross-Linking. This involves scraping off the outer protective layer of the cornea so that treatment can be applied. This is painful for patients and carries many risks. This grant assists in the development of a device that is able to deliver the reagent in a painless, non-invasive, effective and safe way.
Mapping The Dynamics Of Corneal Stem Cell During Aging And After Wounding And Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$548,403.00
Summary
Restoring vision in patients with corneal blindness is our focus. Before this can be achieved we need to understand how corneal stem cells function. For many reasons these studies cannot be performed in man, so we engineered a mouse in which the location, migration, division, differentiation, death of these cells can be followed indefinitely. This information will allow us to improve current therapeutic options and develop new clinical solution for patients with blinding corneal disease.
Gene Identification For Keratoconus - A Blinding Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$912,880.00
Summary
Keratoconus is a common eye disease where the cornea at the front of the eye progressively becomes thinner and bulges out, resulting in severe visual impairment in young people. This project is investigating the genetic causes of keratoconus in a large collection of Australian patients. We aim to be better able to predict who will develop the disease and treat them earlier, as well as be able to target treatments to the causes of disease.
The cornea is essential for vision. Corneal blindness affects all ages, and is often irreversible. Infection of the cornea is a significant cause of corneal blindness. Despite the development of wide-spectrum antibiotics, corneal infections are on the rise. The aim of this project is to provide up-to-date information on the range of bacteria causing corneal infections, their antibiotic sensitivities, and antibiotic prescribing patterns by the ophthalmic profession.
Cultivated Corneal Endothelial Cell Implants For Restoring Vision
Funder
National Health and Medical Research Council
Funding Amount
$886,032.00
Summary
Thousands of Australians each year receive a corneal tissue transplant from the eyes of a deceased organ donor. In the majority of cases these transplants are performed to restore structure and function to the most posterior layer of the cornea – the corneal endothelium. The reliance upon donor tissue, however, presents significant logistical and safety issues. Our goal is therefore to develop improved strategies for treating diseases of the corneal endothelium using cultivated tissue implants.
A Novel Mesenchymal Stromal Cell And Biomaterial For Corneal Reconstruction
Funder
National Health and Medical Research Council
Funding Amount
$508,611.00
Summary
Our research group has identified a new cell type (L-MSC) with the potential to treat a variety of eye diseases. We have also developed a novel material from a protein found in silk, that has potential as a vehicle for delivering healthy cells into diseased eyes. The present project will build upon these promising results by evaluating the properties of L-MSC necessary for clinical use and by testing the feasibility of our new cell delivery system.
Application Of Novel Sutureless Technology For Eye Surgery
Funder
National Health and Medical Research Council
Funding Amount
$342,623.00
Summary
Corneal disease and trauma are major causes of blindness. Corneal trauma requires surgical repair and vision lost from disease may be restored with corneal transplantation. In both cases sutures are used and can have significant complications. Application of a new surgical adhesive for cost-effective, quick and easy corneal surgery with enhanced wound healing is an innovative solution to a major problem in public health with manifold implications in the field of eye surgery
Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.
Therapeutics For Repair And Regeneration Of The Cornea
Funder
National Health and Medical Research Council
Funding Amount
$166,087.00
Summary
Corneal disease is the commonest cause of irreversible blindness and of the 50 million people world-wide who are bilaterally blind, 10 million are blind from corneal involvement. This proposal will address corneal disease by 1. innovative translational research for corneal repair and regeneration; 2. developing evidence-based management guidelines for corneal disease, and 3. by optimising health service delivery.